NEW YORK--(BUSINESS WIRE)--MCO (MyComplianceOffice), a leading provider of compliance technology, has enhanced its platform with Anti-Money Laundering (AML) and Know-Your-Customer (KYC) capabilities.

NEW YORK--(BUSINESS WIRE)--MCO (MyComplianceOffice), a leading provider of compliance technology, continues to deliver on its commitment to helping financial services firms and banks strengthen ...

European Medicines Agency grants MCO-010 five Orphan designations across a wide spectrum of retinal diseases involving photoreceptor loss, including syndromic and non-syndromic, rod- and cone-dominant ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MCO-010 for retinitis pigmentosa is showing promise in ...

REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profile The data ...